Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinomaZiad Bakouny, Srinivas R. Viswanathan, Sarah Abou Alaiwi et al.|Nature Communications|2021Cited by 167
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A. McGregor, Toni K. Choueiri, Rana R. McKay et al.|Journal of Clinical Oncology|2019Cited by 147
Evolution of myeloid-mediated immunotherapy resistance in prostate cancerAram Lyu, Lawrence Fong, Zenghua Fan et al.|Nature|2024Cited by 138
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Dominick Bossé et al.|Cancer Immunology Research|2018Cited by 136
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)Rana R. McKay, Toni K. Choueiri, Bradley A. McGregor et al.|Journal of Clinical Oncology|2020Cited by 105